Article

Disease Modifying Therapies and COVID-19 Severity in Multiple Sclerosis

2020-07-08

Abstract excerpt

Background: Immunosuppressive and immunomodulatory therapies are a major issue during the current coronavirus disease 2019 (Covid-19) pandemic, and in anticipation of possible next waves. <br><br>Methods: In a nationwide study we retrospectively collected data of persons with Multiple Sclerosis (PwMS) with suspected or confirmed Covid-19. We assessed the association of therapies for MS with Covid-19 by...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8ef30bea-5b47-5a5b-a18b-ad20fe6b3963
DOI: 10.2139/ssrn.3631244

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Disease Modifying Therapies and COVID-19 Severity in Multiple SclerosisDOI 10.2139/ssrn.3631244Read

Associations of DMT Therapies with COVID-19 Severity in Multiple Sclerosis: An International Cohort StudySemantic proximity Read

Associations of DMT therapies with COVID-19 severity in multiple sclerosisSemantic proximity Read

COVID-19 Severity in Multiple Sclerosis: Putting Data Into ContextSemantic proximity Read

COVID-19 in Multiple Sclerosis Patients and Risk Factors for Severe InfectionSemantic proximity Read

Chronic Autoimmune Neurological Disorders and Immunosuppression During the COVID-19 PandemicSemantic proximity Read

Increased Rate of Hospitalisation for COVID-19 Amongst Rituximab Treated Multiple Sclerosis Patients: A Study of the Swedish MS RegistrySemantic proximity Read

SARS-CoV-2 infection among patients with multiple sclerosis; A cross-sectional studySemantic proximity Read

COVID-19 in multiple sclerosis patients and risk factors for severe infection.Semantic proximity Read

Impact of mass vaccination on SARS-CoV-2 infections among the total multiple sclerosis population receiving immunomodulatory disease-modifying therapies in EnglandSemantic proximity Read

COVID-19 OUTCOMES IN MS: EARLY EXPERIENCE FROM NYU MULTIPLE SCLEROSIS COMPREHENSIVE CARE CENTERSemantic proximity Read

Multiple sclerosis and neuromyelitis optica spectrum disorders in Argentina: comparing baseline data from the Argentinean MS Registry (RelevarEM).Semantic proximity Read

Prolonged COVID-19 Infection in a Patient with Multiple Sclerosis and Rituximab-TreatmentSemantic proximity Read